Radiologist FDA leader believes generative AI should be evaluated like human docs

Rick Abramson, MD, director of the FDA's Digital Health Center of Excellence, advocates for evaluating generative AI in healthcare with the same scrutiny as human doctors, signalling forthcoming FDA policy development on this issue. The FDA is reviewing public comments and aims to prioritise safety and effectiveness in regulating generative AI medical tools.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.